FDA focus on breakthrough meds is good news, Timmerman writes

01/15/2013 | Xconomy

The pharmaceutical industry's focus will shift toward more groundbreaking, innovative medicines because of the Breakthrough Therapy Designation, the FDA's new regulatory incentive structure, Luke Timmerman writes. The emphasis on breakthrough drugs, together with the high number of drug approvals last year, is a positive development for drugmakers and patients, he writes.

View Full Article in:

Xconomy